ASCO 2021: Updates in Breast Cancer

ASCO 2021: Updates in Breast Cancer

Endocrine Therapy Proves Noninferior to Chemotherapy in HR+, HER2+ Metastatic Breast Cancer

Trastuzumab plus endocrine therapy proved safer than trastuzumab plus CT, with similar survival outcomes, in a phase 3 trial of patients with HR+, HER2+ metastatic breast cancer.

Cancer Therapy Advisor
Use of Integrative Medicine by Patients With Breast Cancer

Nearly three-quarters of patients with breast cancer (73%) reported using at least one type of complementary medicine after cancer diagnosis, while surveyed oncologists believed that...

The ASCO Post
ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer

The first OS analysis of the WSG-ADAPT HR-/HER2+ study, which evaluates neoadjuvant therapy in patients with HR- HER2+ breast cancer, shows that treatment with pertuzumab and trastuzumab plus...

The ASCO Post

Palbociclib Plus Fulvestrant Increases Long-Term Survival in Advanced Breast Cancer

A clinically meaningful long-term improvement in OS was seen with palbociclib plus fulvestrant in patients with HR+ and HER2- advanced breast cancer...

Cancer Therapy Advisor
OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer

One year of adjuvant therapy with the PARP inhibitor olaparib extended DFS in patients with high-risk, early-stage, HER2- breast cancer with BRCA1/2 germline mutations...

The ASCO Post
Novel Gene Panel Predicts Who Can Skip RT in Early Breast Cancer

A novel 16-gene panel based on the biology of locoregional recurrence in early invasive breast cancer can both identify patients with a low risk of recurrence if they were to skip postsurgery RT...

ACE Inhibitor Prevents LVEF Decline After Breast Cancer Drugs

For women with HER2+ early breast cancer treated with an anthracycline-based regimen followed by trastuzumab, concurrent therapy with the ACE inhibitor lisinopril can help to prevent a decline in..

70-Gene MammaPrint Assay Predicts Survival Benefit With Letrozole in Low-Risk Breast Cancer

The 70-gene MammaPrint assay reveals a statistically significant benefit from extended letrozole therapy in patients with low-risk, HR+ breast cancer, per research presented at the 2021 ASCO Annual

Cancer Therapy Advisor
Dual HER2 Blockade With Taxane Improves Pathologic Complete Response and Survival in Breast Cancer

Additional trial results reveal that de-escalated neoadjuvant weekly paclitaxel and dual HER2 blockade leads to excellent pCR and survival in patients with HR-, HER2+ early breast cancer.

Cancer Therapy Advisor
PARP Inhibitor Significantly Improved Disease-Free Survival in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer with BRCA 1/2 Mutations

Adding 1 year of olaparib after completion of standard neoadjuvant or adjuvant chemo, surgery and radiotherapy significantly improved invasive and distant DFS in patients with BRCA1/2 germline muta

Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study

Gilead Sciences today announced new data from the phase 3 ASCENT study evaluating sacituzumab govitecan-hziy in relapsed or refractory metastatic TNBC. The results were presented at the 2021 ASCO A

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program

Merck today announced that data spanning more than 20 cancer types from its oncology research program will be presented at the 2021 ASCO) Annual Meeting.

Phase 1 Data at ASCO Describes Antitumor Activity of Rintodestrant Plus Palbociclib for ER+/HER2- Advanced Breast Cancer

G1 Therapeutics today presented results from its phase 1 study of rintodestrant, demonstrating the drug was very well tolerated and did not result in additional or more severe toxicities when added

BeiGene Presents Clinical Data from Phase 2 Trials of Pamiparib at 2021 ASCO Annual Meeting

BeiGene today announced that its PARP inhibitor pamiparib showed efficacy in patients with HER2-negative breast cancer and demonstrated numerically higher but not statistically significant PFS in g

Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting

Seagen today announced that improvements in OS and PFS were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of tucatinib to trastuzumab and capecitabine

Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations

Agendia announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 ASCO Annual Meeting.

Pharma ASCO: AstraZeneca, Merck to expand Lynparza's blockbuster territory with big early breast cancer showing

Olaparib after surgery in high-risk, HER2-negative early breast cancer reduced the risk of disease recurrence or death by 42% over placebo, according to data presented during the plenary session at

Florida Cancer Specialists & Research Institute Studies Featured at ASCO® 2021 Annual Meeting

Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the ASCO 2021 Annual Meeting.

ASCO 2021: Breast Cancer Sessions Not to Miss

Kathy D. Miller, MD, reviews the breast cancer program at ASCO and shares some insight on sessions that shouldn't be missed!

Breast Cancer Care and Research: What to Expect at ASCO 2021

Sessions will be available on demand beginning Friday, June 4 at 9 AM (ET), with the exception of the Highlights of the Day and broadcast sessions. Broadcast sessions will feature live Q&A with speakers.

Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting

Puma Biotechnology presented results from the phase III ExteNET trial assessing the impact of neratinib treatment duration on OS in patients with early stage HER2+ breast cancer at the virtual 2021


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)